{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-23-000178","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.347037+00:00","generated_at":"2026-06-12T00:52:12.003887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CareDx Q2 2023 revenue $70.3M (-13% YoY); net loss $0.46 per share vs $0.41 loss last year","bullets":["Testing services revenue $53.4M, down 20% YoY due to Medicare Billing Article revisions.","Patient and Digital Solutions revenue $9.0M (+33% YoY); Products revenue $7.9M (+17% YoY).","AlloMap and AlloSure test results ~37,500 (-17% YoY); over 80% adoption of new requisition forms.","Received first multimodal MolDX approval for HeartCare and first dd-cfDNA MolDX approval for AlloSure Lung.","Full year 2023 revenue guidance $240M-$260M; cash and equivalents $283M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-23-000178","json":"https://secwatch.observer/filing/0001217234-23-000178.json","markdown":"https://secwatch.observer/filing/0001217234-23-000178.md","text":"https://secwatch.observer/filing/0001217234-23-000178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/0001217234-23-000178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000178/cdna-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:52:12.003887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}